April 17, 2007 (Los Angeles) -- Two vaccines for preventing cervical cancer, one that is already available and another that is undergoing FDA review, continue to offer nearly 100% protection five years following administration, new research shows.
Darron R. Brown, MD, professor of medicine, microbiology, and immunology at the Indiana University School of Medicine in Indianapolis, says the durability of the protection is an important issue.
"Right now, the data suggest strong sustainability with either vaccine. We don't know if a booster will be needed, but from what we're seeing, I think the vaccines will provide protection for a lifetime," he tells WebMD.
The vaccines were discussed at the annual meeting of the American Association for Cancer Research.
Both vaccines protect against cervical cancer by preventing infection with two strains of human papillomavirus (HPV) -- 16 and 18 -- that are responsible for up to 70% of all cervical cancers.
Gardasil, the approved vaccine, also targets HPV 6 and 11, which account for 90% of genital warts -- providing the woman has not been previously exposed.
HPV is a sexually transmitted virus, with dozens of strains.
The University of Louisville's Stanley Gall, MD, who tested Cervarix, the vaccine under review, predicts it will be approved soon. Then it will be up to each person to decide which one fits her needs, he says.
"They're both wonderful products and the family and their doctor will have to decide which is best," he tells WebMD.
Gall says that younger people are more likely to develop genital warts, so they might decide to opt for the additional protection offered by Gardasil.
Cervical Cancer Vaccine Debate Heats Up
The big, looming issue will not be which vaccine to get, but whether to get it at all, he says. "If we don't get it into people, they won't benefit," he says.
The FDA approved Gardasil for girls and women aged 9-26. The CDC recommends the vaccine to girls 11-12 years old, but it can be given to girls as young as 9. The CDC also recommends it for 13- to 26-year-old females who haven't already received or completed the vaccine series.